This study aimed to develop a transfersomal gel formulation for transdermal delivery of Secnidazole, a BCS class 3 drug known for its high solubility and low permeability. Secnidazole, a nitroimidazole-class drug, is used to treat fungal and yeast infections. Transferosomes, highly flexible supra-molecular aggregates capable of intact penetration through mammalian skin, were utilized for drug encapsulation. Various transfersomal formulations containing different ratios of phospholipids, surfactants, and Carbopol-934 were prepared and evaluated.Results included assessments of entrapment efficiency (EE %), drug content, in-vitro skin permeation studies, and stability tests. Transmission Electron Microscopy confirmed that the vesicles were spherical in shape. Secnidazole was successfully encapsulated with consistent drug content across all formulations. Among them, the transfersomal gel formulation (SG 2) demonstrated superior characteristics with the highest drug content (87.8 ± 3.10%) and cumulative percent drug release (79.8%) over 8 hours.Conclusion: This study concludes that transferosomes represent a promising approach for long-term delivery of Secnidazole, exhibiting satisfactory stability. The findings suggest that transferosomal formulations containing Secnidazole have potential as effective transdermal drug delivery systems for treating bacterial vaginosis infections.